A Schneider1,2, C Johnston1,3, F Tassone1,4, S Sansone1,5, R J Hagerman1,2, E Ferrer6, S M Rivera1,6,7, D Hessl1,3. 1. a MIND Institute, UC Davis Medical Center , Sacramento , CA , USA. 2. c Department of Pediatrics , UC Davis School of Medicine , Sacramento , CA , USA. 3. b Department of Psychiatry and Behavioral Sciences , UC Davis School of Medicine , Sacramento , CA , USA. 4. f Department of Biochemistry and Molecular Medicine , UC Davis , Davis , CA , USA. 5. g Department of Human Development , UC Davis , Davis , CA , USA. 6. d Department of Psychology , UC Davis , Davis , CA , USA. 7. e Center for Mind and Brain, UC Davis , Davis , CA , USA.
Abstract
OBJECTIVE: Clinical observations and a limited number of research studies provide evidence that the fragile X premutation may confer risk for autism, executive dysfunction, and psychopathology. The link to autism spectrum symptoms and social cognition deficits with the premutation remains uncertain, and thus was the focus of the present investigation. METHOD: Our sample included 131 individuals, 42 men/22 women with the FMR1 premutation (mean age = 31.83 ± 8.59 years) with a normal neurological exam, and 48 men/19 women healthy age-matched controls (mean age = 29.48 ± 7.29 years). Individuals completed a comprehensive neuropsychological battery with additional assessments for social cognition, broad autism spectrum, and obsessive-compulsive (OC) symptoms. RESULTS: Premutation carriers self-reported higher rates of autism-related symptoms (Autism Quotient; p = .001). Among males only, premutation carriers showed more atypical social interaction (p < .001) and stereotyped behavior (p = .014) during standardized clinical examination on the Autism Diagnostic Observation Schedule (ADOS) relative to controls. Female premutation carriers reported significantly higher rates of OC symptoms compared to control females (p = .012). Molecular measures defining the expanded premutation (FMR1 CGG repeat length and/or mRNA) were significantly associated with a measure of theory of mind (Reading the Mind in the Eyes Task). CONCLUSIONS: The results of this study indicate a higher rate of broad autism spectrum symptoms in some males with the premutation and provide evidence for an obsessive-compulsive subtype in female premutation carriers.
OBJECTIVE: Clinical observations and a limited number of research studies provide evidence that the fragile X premutation may confer risk for autism, executive dysfunction, and psychopathology. The link to autism spectrum symptoms and social cognition deficits with the premutation remains uncertain, and thus was the focus of the present investigation. METHOD: Our sample included 131 individuals, 42 men/22 women with the FMR1 premutation (mean age = 31.83 ± 8.59 years) with a normal neurological exam, and 48 men/19 women healthy age-matched controls (mean age = 29.48 ± 7.29 years). Individuals completed a comprehensive neuropsychological battery with additional assessments for social cognition, broad autism spectrum, and obsessive-compulsive (OC) symptoms. RESULTS: Premutation carriers self-reported higher rates of autism-related symptoms (Autism Quotient; p = .001). Among males only, premutation carriers showed more atypical social interaction (p < .001) and stereotyped behavior (p = .014) during standardized clinical examination on the Autism Diagnostic Observation Schedule (ADOS) relative to controls. Female premutation carriers reported significantly higher rates of OC symptoms compared to control females (p = .012). Molecular measures defining the expanded premutation (FMR1 CGG repeat length and/or mRNA) were significantly associated with a measure of theory of mind (Reading the Mind in the Eyes Task). CONCLUSIONS: The results of this study indicate a higher rate of broad autism spectrum symptoms in some males with the premutation and provide evidence for an obsessive-compulsive subtype in female premutation carriers.
Entities:
Keywords:
Social cognition; broad autism spectrum phenotype; fragile X premutation; obsessive–compulsive disorder
Authors: David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2005-11-05 Impact factor: 3.568
Authors: A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman Journal: Hum Reprod Date: 2004-12-17 Impact factor: 6.918
Authors: David Hessl; John M Wang; Andrea Schneider; Kami Koldewyn; Lien Le; Christine Iwahashi; Katherine Cheung; Flora Tassone; Paul J Hagerman; Susan M Rivera Journal: Biol Psychiatry Date: 2011-07-23 Impact factor: 13.382
Authors: Molly Losh; Jessica Klusek; Gary E Martin; John Sideris; Morgan Parlier; Joseph Piven Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2012-06-12 Impact factor: 3.568
Authors: Molly Winston; Kritika Nayar; Abigail L Hogan; Jamie Barstein; Chelsea La Valle; Kevin Sharp; Elizabeth Berry-Kravis; Molly Losh Journal: Physiol Behav Date: 2019-11-22
Authors: Anne C Wheeler; Angela Gwaltney; Melissa Raspa; Katherine C Okoniewski; Elizabeth Berry-Kravis; Kelly N Botteron; Dejan Budimirovic; Heather Cody Hazlett; David Hessl; Molly Losh; Gary E Martin; Susan M Rivera; Jane E Roberts; Donald B Bailey Journal: Pediatrics Date: 2021-05 Impact factor: 7.124
Authors: Nell Maltman; Janna Guilfoyle; Kritika Nayar; Gary E Martin; Molly Winston; Joseph C Y Lau; Lauren Bush; Shivani Patel; Michelle Lee; John Sideris; Deborah A Hall; Lili Zhou; Kevin Sharp; Elizabeth Berry-Kravis; Molly Losh Journal: Front Psychiatry Date: 2021-08-06 Impact factor: 5.435